Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHEA in Synovial Sarcoma
NCT02683148Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2016
- Primary completion
- Sep 2018
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label trial of dehydroepiandrosterone in synovial sarcoma (SS) (4 arms), sponsored by Washington University School of Medicine. Primary endpoints: Maximum tolerated dose at 2 years and Progression-free rate at 5 years. Started Sep 2016; status: terminated.
02
Drugs
dehydroepiandrosterone
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT02683148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02683148.